New! View global litigation for patent families

WO2007066823A1 - Antibody against connective tissue growth factor or composition containing the same - Google Patents

Antibody against connective tissue growth factor or composition containing the same

Info

Publication number
WO2007066823A1
WO2007066823A1 PCT/JP2006/324894 JP2006324894W WO2007066823A1 WO 2007066823 A1 WO2007066823 A1 WO 2007066823A1 JP 2006324894 W JP2006324894 W JP 2006324894W WO 2007066823 A1 WO2007066823 A1 WO 2007066823A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
antibody
ctgf
high
diseases
fragment
Prior art date
Application number
PCT/JP2006/324894
Other languages
French (fr)
Japanese (ja)
Inventor
Poh Sing Ng
Koki Endo
Megumi Iijima
Tomohiro Mori
Original Assignee
Nosan Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders

Abstract

It is intended to provide an antibody, which can specifically recognize a high-order structure of the natural type of CTGF at a high affinity or its fragment, a composition comprising this antibody or its fragment which is usable in treating, preventing or diagnosing CTGF-related diseases such as fibrosis or cell proliferative diseases, and a method of producing the above antibody.
PCT/JP2006/324894 2005-12-07 2006-12-07 Antibody against connective tissue growth factor or composition containing the same WO2007066823A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2005-353628 2005-12-07
JP2005353628A JP2009067678A (en) 2005-12-07 2005-12-07 Antibody against connective tissue growth factor or composition containing the same

Publications (1)

Publication Number Publication Date
WO2007066823A1 true true WO2007066823A1 (en) 2007-06-14

Family

ID=38122955

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/324894 WO2007066823A1 (en) 2005-12-07 2006-12-07 Antibody against connective tissue growth factor or composition containing the same

Country Status (2)

Country Link
JP (1) JP2009067678A (en)
WO (1) WO2007066823A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009072588A1 (en) * 2007-12-05 2009-06-11 Nihon University Monoclonal antibody responsive to mouse polymeric immunoglobulin receptor
EP2564866A2 (en) * 2010-04-28 2013-03-06 Postech Academy-Industry Foundation Pharmaceutical composition using connective tissue growth factor
WO2013094723A1 (en) 2011-12-22 2013-06-27 アステラス製薬株式会社 Novel anti-human ctgf antibody
WO2013108869A1 (en) * 2012-01-20 2013-07-25 国立大学法人岡山大学 Therapeutic or prophylactic agent for cancer
EP2964330A4 (en) * 2013-03-08 2016-08-31 Univ Vermont Compositions and methods for cardiac tissue repair

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2435074B1 (en) * 2009-05-28 2015-11-25 Abbott Biologicals B.V. Extraneous agents testing

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029442A1 (en) * 1998-11-16 2000-05-25 Genovac Ag Method for producing antibodies acting against a polypeptide that only recognises the coding nucleic acid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029442A1 (en) * 1998-11-16 2000-05-25 Genovac Ag Method for producing antibodies acting against a polypeptide that only recognises the coding nucleic acid

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOYLE J.S. ET AL: "DNA immunization: Induction of higher avidity antibody and effect of route on T cell cytotoxicity", PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 14626 - 14631, XP003014106 *
HOSEI K.I. ET AL: "DNA Men'ekiho ni yoru Hito Ketsugo Soshiki Seicho Inshi (CTGF) ni Taisuru Tokui Kotai no Kaihatsu", DAI 28 KAI ANNUAL MEETING OF THE MOLECULAR BIOLOGY SOCIETY OF JAPAN KOEN YOSHISU, 25 November 2005 (2005-11-25), ABSTRACT, pages 768 - 3P-1222, XP003014104 *
MINATO M. ET AL: "Module-specific antibodies against human connective tissue growth factor: utility for structural and functional analysis of the factor as related to chondrocytes", JOURNAL OF BIOCHEMISTRY, vol. 135, no. 3, 2004, pages 347 - 354, XP003014105 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009137859A (en) * 2007-12-05 2009-06-25 Univ Nihon Monoclonal antibody reactive with mouse polymeric immunoglobulin receptor
WO2009072588A1 (en) * 2007-12-05 2009-06-11 Nihon University Monoclonal antibody responsive to mouse polymeric immunoglobulin receptor
JP2013530934A (en) * 2010-04-28 2013-08-01 ポステック アカデミー−インダストリー ファンデーション Pharmaceutical compositions using the connective tissue growth factor
EP2564866A2 (en) * 2010-04-28 2013-03-06 Postech Academy-Industry Foundation Pharmaceutical composition using connective tissue growth factor
US8859496B2 (en) 2010-04-28 2014-10-14 Postech Academy-Industry Foundation Pharmaceutical composition using connective-tissue growth factor
EP2564866A4 (en) * 2010-04-28 2013-11-27 Postech Acad Ind Found Pharmaceutical composition using connective tissue growth factor
CN104011206A (en) * 2011-12-22 2014-08-27 安斯泰来制药株式会社 Novel anti-human ctgf antibody
WO2013094723A1 (en) 2011-12-22 2013-06-27 アステラス製薬株式会社 Novel anti-human ctgf antibody
JPWO2013094723A1 (en) * 2011-12-22 2015-04-27 アステラス製薬株式会社 New anti-human antibody ctgf
US9587015B2 (en) 2011-12-22 2017-03-07 Astellas Pharma Inc. Anti-human CTGF antibody
WO2013108869A1 (en) * 2012-01-20 2013-07-25 国立大学法人岡山大学 Therapeutic or prophylactic agent for cancer
EP2964330A4 (en) * 2013-03-08 2016-08-31 Univ Vermont Compositions and methods for cardiac tissue repair
US9707271B2 (en) 2013-03-08 2017-07-18 University Of Vermont And State Agriculture College Methods for enhancing cardiac function with the combination of CTGF and insulin or IGF-1

Also Published As

Publication number Publication date Type
JP2009067678A (en) 2009-04-02 application

Similar Documents

Publication Publication Date Title
WO2004029207A3 (en) Optimized fc variants and methods for their generation
WO2007049608A1 (en) Polymer structure whose surface and/or interface is modified, and method for producing same
WO2004016740A3 (en) Humanized rabbit antibodies
WO2006085518A1 (en) Method for improving antibody
WO2006137514A1 (en) Therapeutic agent for cancer comprising substance capable of inhibiting expression or function of synoviolin as active ingredient and screening method for the therapeutic agent for cancer
WO2007026689A1 (en) Antibody produced using ostrich and method for production thereof
Smak Enhanced Mass Transfer in Dwarf Novae of the SU UMa Type During Their Outbursts and Superoutbursts
WO2007059430A3 (en) Moesin, caveolin 1 and yes associated protein 1 as predictive markers of response to dasatinib in breast cancers
WO2007039986A1 (en) Method of obtaining pancreatic endocrine cells from adipose tissue-origin cells
WO2004058820A3 (en) Single-domain-effector group and its uses
WO2004020633A1 (en) Human antihuman interleukin-6 antibody and fragment of the antibody
WO2007059135A3 (en) Methods of treating alzheimer's disease
WO2003008592A1 (en) Polyfunctional stem cells originating in adipose tissue
WO2004039948A3 (en) Actriib fusion polypeptides and uses therefor
WO2005115440A3 (en) Compositions and method for modulating insulin-activated nitric oxide synthase
WO2005018572A3 (en) Improved antibodies having altered effector function and methods for making the same
WO2004084923A1 (en) Antistress agent
WO2002089747A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002060317A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2002100914A3 (en) Polymeric material, containing a latent acid
WO2007053685A3 (en) Methods of treating atrial fibrillation with p38 inhibitor compounds
WO2005040361A1 (en) Method of simply preparing stem cell and feeder cell to be used therein
WO2006044334A3 (en) Platelet-derived growth factor compositions and methods of use thereof
WO2003091449A1 (en) Method of measuring neprilysin activity
WO2004046365A3 (en) Interferon-alpha polypeptides and conjugates

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06834648

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: JP